Autres langues Nurix Therapeutics, Inc.

Actions

NRIX

US67080M1036

Temps réel estimé Cboe BZX Autres places de cotation 19:21:56 17/05/2024			Varia. 5j.	Varia. 1 janv.
16,54 ^USD	+7,37 %		+22,21 %	+59,98 %

14/05	NURIX THERAPEUTICS, INC. : Stephens Inc. toujours positif	ZM
12/04	Le secteur des soins de santé est stable avant la cloche vendredi	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)	14/05
Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference	07/05
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares	17/04
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering	15/04
Sector Update: Health Care Stocks Steady Pre-Bell Friday	12/04
Sector Update: Health Care	12/04
North American Morning Briefing : Big Banks Kick off Earnings Season	12/04
Nurix Therapeutics Prices Upsized Stock Offering at $15 a Share	12/04
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering	12/04
Nurix Therapeutics Launching Public Offering -- Shares Fall After-Hours	11/04
Nurix Therapeutics Announces Proposed Public Offering	11/04
Nurix Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024	10/04
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update	10/04
Earnings Flash (NRIX) NURIX THERAPEUTICS Reports Q1 Revenue $16.6M	10/04
North American Morning Briefing : Traders Await -2-	10/04
Nurix Therapeutics Shares Climb 19% on Extended Sanofi Collaboration	09/04
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies	09/04
Nurix Therapeutics, Inc. Reports First Clinical Evidence of CNS Activity of NX-5948, A Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies	09/04
Nurix Therapeutics Extends Collaboration With Sanofi, Aims to Nominate Clinical Candidate	09/04
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6	09/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Nurix Therapeutics, Inc.

Actions

NRIX

US67080M1036

Autres langues

Filtres